This process is marked by chronic low-grade inflammation (inflammaging), diminished adaptive immunity, and a skewed CD4+/CD8+ T cell ratio, leaving older adults more vulnerable to infection, cancer, and poor vaccine responses [47]
If and when the FDA declares an end to the semaglutide shortage, Cook said Noom would continue offering branded GLP-1 treatments and other weight-loss medications to its members
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (under the brand names Ozempic and Rybelsus), chronic weight management (Wegovy), and cardiovascular risk reduction in specific populations
The goal is to support digestion while the body adapts to the medication without stopping treatment altogether
This precautionary approach, while not a labeled restriction, represents good clinical practice